<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543296</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00013641</org_study_id>
    <nct_id>NCT00543296</nct_id>
  </id_info>
  <brief_title>Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment</brief_title>
  <official_title>Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect data on patients with severe uveitis that have
      required re-implantation of the sustained-release fluocinolone drug delivery device due to
      depletion of study drug in their previous implanted device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To collect medical information on a sustained release drug delivery system that
      delivers the corticosteroid, fluocinolone acetonide, directly into the vitreous cavity of the
      eye. This system has the potential to maintain therapeutic drug levels in the eye while
      reducing systemic exposure to the drug to negligible levels. RetisertTM is the trade name for
      the intravitreal fluocinolone acetonide implant.

      Hypothesis: The RetisertTM will be a safe and effective method to manage patients with severe
      uveitis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Eyes With Inflammation Recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Number of eyes with inflammation recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes With Improvement in Visual Acuity</measure>
    <time_frame>baseline to 52 weeks</time_frame>
    <description>Visual acuity was improved by two or more lines from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant's Eye Requiring Adjunctive Therapy</measure>
    <time_frame>5 years</time_frame>
    <description>Adjunctive Therapy needed to control inflammation in the implanted eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Increased Intraocular Pressure</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>0.59 mg Fluocinolone Acetonide implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.59 mg Fluocinolone Acetonide implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.59 mg Fluocinolone Acetonide implant</intervention_name>
    <description>0.59 mg Fluocinolone Acetonide implant</description>
    <arm_group_label>0.59 mg Fluocinolone Acetonide implant</arm_group_label>
    <other_name>Retisert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-infectious intermediate, posterior or panuveitis

          -  Previous placement of fluocinolone acetonide implant with initial uveitis quiescence
             and subsequent recurrence of inflammation once implant depleted of drug

        Exclusion Criteria:

          -  Infectious uveitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn J Jaffe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <results_first_submitted>August 8, 2013</results_first_submitted>
  <results_first_submitted_qc>June 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2014</results_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveitis</keyword>
  <keyword>Cystoid Macular Edema (CME)</keyword>
  <keyword>fluocinolone acetonide</keyword>
  <keyword>non-infectious uveitis affecting the posterior segment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluocinolone Acetonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of these 21 subjects, 14 subjects had recurrence of inflammation and were re-implanted</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>0.59 mg Fluocinolone Acetonide Implant</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of 21 consented subjects only 14 completed the 9 months follow-up in whom fluocinolone acetonide implants were replaced or who needed a second implant.</population>
      <group_list>
        <group group_id="B1">
          <title>0.59 mg Fluocinolone Acetonide Implant</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Eyes With Inflammation Recurrence</title>
        <description>Number of eyes with inflammation recurrence</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.59 mg Fluocinolone Acetonide Implant</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Inflammation Recurrence</title>
          <description>Number of eyes with inflammation recurrence</description>
          <units>eye with inflammation</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of eyes implanted</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes With Improvement in Visual Acuity</title>
        <description>Visual acuity was improved by two or more lines from baseline.</description>
        <time_frame>baseline to 52 weeks</time_frame>
        <population>There were 14 participants studied with a total of 17 eyes implanted. Of the 17 eyes each could require separate adjunctive therapy</population>
        <group_list>
          <group group_id="O1">
            <title>0.59 mg Fluocinolone Acetonide Implant</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Improvement in Visual Acuity</title>
          <description>Visual acuity was improved by two or more lines from baseline.</description>
          <population>There were 14 participants studied with a total of 17 eyes implanted. Of the 17 eyes each could require separate adjunctive therapy</population>
          <units>percentage of eyes improved</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of eyes implanted</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant's Eye Requiring Adjunctive Therapy</title>
        <description>Adjunctive Therapy needed to control inflammation in the implanted eye</description>
        <time_frame>5 years</time_frame>
        <population>There were 14 participants studied with a total of 17 eyes implanted. Of the 17 eyes each could require separate adjunctive therapy</population>
        <group_list>
          <group group_id="O1">
            <title>0.59 mg Fluocinolone Acetonide Implant</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant's Eye Requiring Adjunctive Therapy</title>
          <description>Adjunctive Therapy needed to control inflammation in the implanted eye</description>
          <population>There were 14 participants studied with a total of 17 eyes implanted. Of the 17 eyes each could require separate adjunctive therapy</population>
          <units>participant's eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of eyes implanted</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Topical corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SubTenon triamcinolone acetonide injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prednisone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intravitreal triamcinolone acetonide injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Increased Intraocular Pressure</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.59 mg Fluocinolone Acetonide Implant</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Increased Intraocular Pressure</title>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of eyes implanted</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.59 mg Fluocinolone Acetonide Implant</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinial Detachment</sub_title>
                <description>Retinal Detachment is a known risk of ocular surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <description>Endophthalmitis is a known risk of ocular surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glenn J. Jaffe, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-4458</phone>
      <email>jaffe001@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

